Aquestive Therapeutics Inc (AQST)
2.315
0.00 (0.00%)
USD |
NASDAQ |
Jun 26, 13:02
Aquestive Therapeutics Cash from Investing (Quarterly): -0.029M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.029M |
| December 31, 2023 | -0.016M |
| September 30, 2023 | -0.151M |
| June 30, 2023 | -0.826M |
| March 31, 2023 | -0.002M |
| December 31, 2022 | -0.026M |
| September 30, 2022 | -1.717M |
| June 30, 2022 | -0.677M |
| March 31, 2022 | -0.104M |
| December 31, 2021 | -0.533M |
| September 30, 2021 | -0.083M |
| June 30, 2021 | -0.194M |
| March 31, 2021 | -0.103M |
| December 31, 2020 | -0.236M |
| September 30, 2020 | -0.038M |
| Date | Value |
|---|---|
| June 30, 2020 | -0.112M |
| March 31, 2020 | -0.131M |
| December 31, 2019 | -0.086M |
| September 30, 2019 | -0.091M |
| June 30, 2019 | -0.11M |
| March 31, 2019 | -0.376M |
| December 31, 2018 | -0.49M |
| September 30, 2018 | -0.448M |
| June 30, 2018 | -0.627M |
| March 31, 2018 | -0.259M |
| December 31, 2017 | -0.088M |
| September 30, 2017 | -0.433M |
| June 30, 2017 | -0.89M |
| March 31, 2017 | -0.657M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-1.717M
Minimum
Sep 2022
-0.002M
Maximum
Mar 2023
-0.2632M
Average
-0.107M
Median
Cash from Investing (Quarterly) Benchmarks
| Humacyte Inc | -0.391M |
| Heron Therapeutics Inc | 1.278M |
| Revance Therapeutics Inc | -31.71M |
| Verrica Pharmaceuticals Inc | 0.00 |
| Akebia Therapeutics Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.38M |
| Cash from Financing (Quarterly) | 81.74M |
| Free Cash Flow | -26.60M |
| Free Cash Flow Per Share (Quarterly) | -0.1415 |
| Free Cash Flow to Equity (Quarterly) | -11.66M |
| Free Cash Flow to Firm (Quarterly) | -6.542M |
| Free Cash Flow Yield | -17.48% |